Clinical Trial Update: Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients [Phase 1]

View source ↗

Summary

Completion of a Phase I safety and tolerability study of Cediranib (RECENTIN™, AZD2171) in combination with chemotherapy for first-line lung cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Cediranib (RECENTIN™, AZD2171) (cediranib)

Snippet

Sponsor: AstraZeneca | Conditions: Lung Cancer | Phase 1 | Status: COMPLETED